Mather Group LLC. Sells 705 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Mather Group LLC decreased its holdings in Thermo Fisher Scientific Inc. by 30.5%, selling 705 shares, which left them with a total of 1,607 shares valued at approximately $652,000.
• Analysts' opinions on Thermo Fisher are mixed, with HSBC Global Research downgrading the stock to a "hold" while UBS Group raised its price target to $500, indicating a consensus rating of "Moderate Buy."
• The company announced a quarterly dividend of $0.43 per share, payable on October 15th, contributing to an annualized dividend yield of 0.4%.

Mather Group LLC. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 30.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,607 shares of the medical research company's stock after selling 705 shares during the period. Mather Group LLC.'s holdings in Thermo Fisher Scientific were worth $652,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the stock. Foster Victor Wealth Advisors LLC increased its position in shares of Thermo Fisher Scientific by 5.2% during the second quarter. Foster Victor Wealth Advisors LLC now owns 529 shares of the medical research company's stock worth $222,000 after acquiring an additional 26 shares during the period. Northside Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 1,015.4% during the second quarter. Northside Capital Management LLC now owns 5,800 shares of the medical research company's stock worth $2,352,000 after acquiring an additional 5,280 shares during the period. IMS Capital Management purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $343,000. DB Fitzpatrick & Co Inc increased its position in shares of Thermo Fisher Scientific by 20.0% during the second quarter. DB Fitzpatrick & Co Inc now owns 3,898 shares of the medical research company's stock worth $1,580,000 after acquiring an additional 649 shares during the period. Finally, Accurate Wealth Management LLC increased its position in shares of Thermo Fisher Scientific by 15.5% during the second quarter. Accurate Wealth Management LLC now owns 789 shares of the medical research company's stock worth $338,000 after acquiring an additional 106 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on TMO shares. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a report on Friday, July 11th. Finally, Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Sixteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $588.35.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $459.34 on Friday. The firm has a market capitalization of $173.45 billion, a PE ratio of 26.57, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77. The company's fifty day moving average price is $475.73 and its 200-day moving average price is $448.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.